April 11, 2022
As reported by the Financial Post, Organovo Holdings, Inc. and BICO (formerly Cellink) have reached a broad licensing agreement that will allow BICO and its affiliate companies access to Organovo’s foundational patent portfolio in 3D bioprinting.
Organovo and BICO were previously involved in several legal disputes surrounding the bioprinting patents.
As part of the new patent licence agreement, all civil actions regarding patent infringement and intellectual property rights dealing with the validity of the Organovo patents will reportedly be dismissed and/or terminated.
Authors: Farrah Kudus and Larissa Fulop